<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Korean J Anesthesiol</journal-id><journal-id journal-id-type="publisher-id">KJAE</journal-id><journal-title-group><journal-title>Korean Journal of Anesthesiology</journal-title></journal-title-group><issn pub-type="ppub">2005-6419</issn><issn pub-type="epub">2005-7563</issn><publisher><publisher-name>The Korean Society of Anesthesiologists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20498780</article-id><article-id pub-id-type="pmc">2872845</article-id><article-id pub-id-type="doi">10.4097/kjae.2010.58.3.290</article-id><article-categories><subj-group subj-group-type="heading"><subject>Experimental Research Article</subject></subj-group></article-categories><title-group><article-title>Effects of postconditioning with N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine in isolated rat hearts</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Joon Hong</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Joon</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Yong-Hyeon</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cheun</surname><given-names>Kook Jin</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jang</surname><given-names>Young-Ho</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Anesthesiology and Pain Medicine, Pureun Burn Hospital, Daegu, Korea.</aff><aff id="A2"><label>2</label>Institute of Cardiovascular Research, Pusan National University Yangsan Hospital, Yangsan, Korea.</aff><author-notes><corresp>Corresponding author: Young-Ho Jang, M.D., Ph.D., Institute of Cardiovascular Research, Pusan National University Yangsan Hospital, Beomeo-ri, Mulgeum-eup, Yangsan 626-770, Korea. Tel: 82-55-360-1459, Fax: 82-55-360-2204, <email>weonjo@pnuyh.co.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>29</day><month>3</month><year>2010</year></pub-date><volume>58</volume><issue>3</issue><fpage>290</fpage><lpage>295</lpage><history><date date-type="received"><day>05</day><month>10</month><year>2009</year></date><date date-type="rev-recd"><day>07</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Korean Society of Anesthesiologists, 2010</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>It was reported that N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine (TPEN), a transition metal chelator, confers cardioprotection against myocardial ischemic injury. In this study, we investigated the effect of TPEN targeting reperfusion period in isolated rat hearts.</p></sec><sec><title>Methods</title><p>Langendorff perfused rat hearts were subjected to 30 min of regional ischemia and 2 h of reperfusion. Hearts were randomly assigned to either control (n = 9) or 10 &#x000b5;M of TPEN (n = 8) groups. TPEN was perfused for a period of 5 min before and 30 min after reperfusion.</p></sec><sec><title>Results</title><p>The ratio of infarct area/ischemic area (AN/AR) was significantly reduced in TPEN treated hearts (6.9 &#x000b1; 1.7%, P &#x0003c; 0.001) compared to control hearts (29.5 &#x000b1; 3.2%). Recovery of left ventricular developed pressure (LVDP), rate-pressure product (RPP), +dP/dt<sub>max</sub>, and -dP/dt<sub>min</sub> in the control group after reperfusion were 53.8 &#x000b1; 6.2%, 51.0 &#x000b1; 6.3%, 51.9 &#x000b1; 5.7%, and 51.4 &#x000b1; 5.7%, respectively, of the baseline levels. In the TPEN group, LVDP, RPP, +dP/dt<sub>max</sub>, and -dP/dt<sub>min</sub> returned to 58.5 &#x000b1; 4.6%, 54.8 &#x000b1; 6.4%, 61.7 &#x000b1; 4.9%, and 53.4 &#x000b1; 3.9%, respectively, of the baseline levels. There were no significant differences in the cardiodynamic variables between the two groups (P &#x0003e; 0.05).</p></sec><sec><title>Conclusions</title><p>Pharmacological postconditioning with TPEN reduces myocardial infarction however, TPEN does not modify post-ischemic systolic dysfunction in isolated rat hearts.</p></sec></abstract><kwd-group><kwd>Heart</kwd><kwd>Myocardial stunning</kwd><kwd>Postconditioning</kwd><kwd>Reperfusion injury</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Because pretreatment with ischemic or pharmacological preconditioning is seldom possible in patients with ongoing acute myocardial infarction, strategies that directly target reperfusion could be more reliable. In this regard, ischemic postconditioning (I-Post) and pharmacological postconditioning (P-Post) have generated considerable interest recently. I-Post, which entails brief repetitive mechanical interruptions during early reperfusion, has reduced myocardial infarction in dogs [<xref ref-type="bibr" rid="B1">1</xref>], rodents [<xref ref-type="bibr" rid="B2">2</xref>], and even humans [<xref ref-type="bibr" rid="B3">3</xref>]. The infarct limitation effect by I-Post is as effective as that of ischemic preconditioning (I-Pre) [<xref ref-type="bibr" rid="B1">1</xref>]. In addition, P-Post with various adjuvants, such as opioid, bradykinin, insulin, and urocontin, has also been shown to provide cardioprotection [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>].</p><p>N,N,N'N'-Tetrakis-[2-pyridylmethyl]-ethylenediamine (TPEN) is a high-affinity chelator of transition metals, such as Zn<sup>2+</sup>. TPEN also binds Ca<sup>2+</sup> with a low affinity, and its fast diffusion across membranes renders it an intracellular Ca<sup>2+</sup> buffer [<xref ref-type="bibr" rid="B8">8</xref>]. It has been proposed that ischemic pretreatment with TPEN confers cardioprotection in rat cardiomyocytes [<xref ref-type="bibr" rid="B9">9</xref>] and hearts [<xref ref-type="bibr" rid="B10">10</xref>], and TPEN treatment before and during hypoxia induces activation of a sarcolemmal Na<sup>+</sup>/Ca<sup>2+</sup> exchanger and increases Ca<sup>2+</sup> extrusion from the cytoplasm of cardiomyocytes, preventing cytosolic Ca<sup>2+</sup> overload in cultured cardiomyocytes [<xref ref-type="bibr" rid="B9">9</xref>]. Furthermore, TPEN administered prior to ischemia has exerted beneficial effects on post-ischemic cardiac function; it has also reduced ventricular fibrillation (VF) incidence as well as the incidence and duration of ventricular tachycardia in in vivo rat hearts [<xref ref-type="bibr" rid="B10">10</xref>]. However, the TPEN induced myocardial infarct limitation effect, which is considered a more reliable endpoint than functional recovery [<xref ref-type="bibr" rid="B11">11</xref>], has not been characterized.</p><p>Interestingly, some drugs protect the myocardium against ischemic injury but not against reperfusion injury and vice versa [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. In this regard, it should be determined whether TPEN also provides cardioprotection when administered during the reperfusion period, which is a more suitable management time in clinical settings. Thus far, however, there is scant information about targeting TPEN during the reperfusion phase and the subsequent effects it would have on infarct limitation and cardiac function recovery.</p><p>Therefore, in this study, we examined whether P-Post with TPEN at the concentrations that are cardioprotective against ischemia could reduce myocardial infarct size and induce cardiodynamic functional recovery in an isolated rat heart model.</p></sec><sec sec-type="methods"><title>Materials and Methods</title><sec><title>Langendorff isolated heart perfusion preparation</title><p>Male Sprague-Dawley rats (280-330 gm) were obtained from Korea Taconic Company. Rats were anesthetized with 100 mg/kg of pentobarbital sodium (Entobar&#x000ae;, Hanlim Pharmacy, Korea), and 300 IU of heparin was administered intraperitoneally. Coronary perfusion by the Langendorff system with modified Krebs-Henseleit (KH) solution, containing 118.5 NaCl, 4.7 KCl, 1.2 MgSO<sub>4</sub>, 1.8 CaCl<sub>2</sub>, 24.8 NaHCO<sub>3</sub>, 1.2 KH<sub>2</sub>PO<sub>4</sub>, and 10 glucose (in mM), was performed as previously described in detail in our previous reports [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>].</p></sec><sec><title>Making of ischemia and reperfusion</title><p>All hearts were allowed to stabilize for at least 20 min before ischemia induction. Hearts were subjected to 30 min of regional ischemia and 120 min of reperfusion. To induce regional ischemia, a snare was made at the level of the proximal length of the left coronary artery (LCA). Regional ischemia was induced by pulling the snare and confirmed by regional cyanosis and a substantial decrease in left ventricular developed pressure (LVDP). Reperfusion was started by releasing the snare. Hearts experiencing VF after reperfusion usually revert spontaneously to sinus rhythm. VF lasting more than 30 s was treated with finger flick cardioversion until a perfusing rhythm was obtained. No pharmacological agents were used for defibrillation.</p></sec><sec><title>Assessment of cardiac function</title><p>In isolated hearts, a KH buffer-filled latex balloon was inserted into the left ventricle (LV) and was adjusted to 5-10 mmHg of the left ventricular end-diastolic pressure (LVEDP) at the beginning of the experiment. Cardiodynamic variables, including heart rate (HR), left ventricular systolic pressure (LVSP), and LVEDP, were recorded with the MP150 system (BIOPAC Systems Inc., USA). LVDP and rate-pressure product (RPP) were calculated as follows: LVDP = LVSP - LVEDP and RPP = LVDP &#x000d7; HR. Maximum (+dP/dt<sub>max</sub>) and minimum (-dP/dt<sub>min</sub>) of the first derivative of LV pressure were analyzed using the Acqknowledge software (version 3.9.0.). Coronary flow (CF) was measured by perfusate dripping from the right heart into a graduated cylinder.</p></sec><sec><title>Experimental protocol</title><p>Isolated rat hearts were assigned randomly to one of the following two groups: 1) Control; no other intervention either before or after LCA occlusion (n = 9), and 2) TPEN; 10 &#x000b5;M of TPEN (n = 8). TPEN (Sigma-Aldrich Chemical, USA) was infused for a period of 5 min before and 30 min after reperfusion (<xref ref-type="fig" rid="F1">Fig. 1</xref>). TPEN was dissolved with dimethyl sulfoxide and stored at -20&#x02103;. TPEN was diluted with KH solution to the required final concentrations, as described above, on the day of each experiment. The concentration of TPEN used in this study was based on a previous study for isolated working rat hearts [<xref ref-type="bibr" rid="B10">10</xref>].</p></sec><sec><title>Exclusion criteria</title><p>We decided prospectively that any hearts with a HR &#x0003c; 250 beats/min, those failing to develop LVSP &#x0003e; 80 mmHg when the LVEDP was kept at 5-10 mmHg, or CF &#x0003e; 18 ml/min or &#x0003c; 8 ml/min at the end of stabilization would be excluded from the study.</p></sec><sec><title>Determination of ischemic and infarct zone</title><p>At the end of each experiment (2 h reperfusion), ischemic (area at risk, AR) and infarcted (area of necrosis, AN) regions were measured with fluorescent polymer microspheres (Duke Scientific Corp., USA) and 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich Chemical, USA) staining as described previously [<xref ref-type="bibr" rid="B15">15</xref>]. The AR and AN regions were quantified with the ImageTool program (UTHSCSA Image Tool, version 3.0). Infarct size was expressed as a percentage of the risk zone (AN/AR). All measurements were performed in a blinded fashion. Body weight (mean 302.2 &#x000b1; 4.4 gm) and heart weight (mean 1.54 &#x000b1; 0.04 gm) were equivalent between the two groups.</p></sec><sec><title>Statistical analysis</title><p>Data are expressed as means &#x000b1; SEM. Statistical significance was determined using a t-test (SPSS for Windows, version 12.0). A P value less than 0.05 was considered to be statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>All hearts for this experiment were perfused within 30 s after excision. A total of 19 rat hearts were used for the infarct size measurement study. Two hearts were excluded for the following reasons: HR &#x0003c; 250 beats/min (1) and CF &#x0003e; 18 ml/min (1) after the stabilization period. Therefore, we report the data for 17 hearts that successfully completed the infarct experiment study. The incidence of VF during the first 30 min after reperfusion was 67% (6/9) in the control group and 62% (5/8) in the TPEN group, respectively. Statistical analysis was not performed for the occurrence of VF, because of the small sample size. Hearts experiencing VF after reperfusion usually reverted to sinus rhythm spontaneously or by finger flick cardioversion.</p><sec><title>Infarct size</title><p><xref ref-type="fig" rid="F2">Fig. 2</xref> represents the AN/AR ratio after 2 h of reperfusion by TTC stain. AN in control hearts was 29.5 &#x000b1; 3.2% of the AR, which is in agreement with our recently reported infarct measurement study [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. AN/AR of the TPEN group was significantly reduced (6.9 &#x000b1; 1.7%) compared to control hearts (P &#x0003c; 0.001).</p></sec><sec><title>Functional recovery</title><p>Baseline CF and HR after stabilization are shown in <xref ref-type="table" rid="T1">Table 1</xref> and were comparable between the groups, averaging 11.8 &#x000b1; 0.5 ml/min and 273.6 &#x000b1; 3.1 beats/min, respectively. CF abruptly decreased after ischemia and diminished continuously during reperfusion without achieving statistically significant differences between the two groups. There was no statistically significant difference in HR throughout the experiment between the groups (data not shown).</p><p>Baseline values of cardiodynamic parameters after stabilization are also shown in <xref ref-type="table" rid="T1">Table 1</xref>. There was no significant difference in baseline cardiodynamic parameters between the two groups (P &#x0003e; 0.05). <xref ref-type="fig" rid="F3">Fig. 3</xref> shows recovery of LVDP, RPP, +dP/dt<sub>max</sub>, and -dP/dt<sub>min</sub> after 2 h of reperfusion compared to baseline levels. There were no significant differences in cardiodynamic variables between the two groups (P &#x0003e; 0.05).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>TPEN is a drug that was proposed to protective against myocardial ischemic injury and reduce post-ischemic cardiac damage [<xref ref-type="bibr" rid="B17">17</xref>]. Until now, most of the studies on TPEN's cardioprotective effect were performed on ischemic pretreatment, and the effect of P-Post with TPEN remained. The present study has shown for the first time that targeting the use of TPEN, a metal chelator, during the reperfusion phase limits myocardial infarction. In addition, the study showed that there were no differences in cardiodynamic parameters, such as LVDP, RPP, +dP/dt<sub>max</sub>, and -dP/dt<sub>min</sub>, between TPEN-treated and non-treated hearts. Our data showed that P-Post with TPEN reduces myocardial infarct size but does not improve the functional recovery after reperfusion in isolated rat hearts.</p><p>Although tissue salvage by an anti-infarct intervention leads to improvement of cardiac function, infarct size limitation does not always produce mechanical functional recovery of hearts after myocardial ischemic/reperfusion (I/R) injury. For example, a potent opioid such as fentanyl, or angiotensin II reduces infarct size but does not protect against myocardial dysfunction in isolated rat hearts [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. In addition, there are also several lines of evidence that I-Pre and I-Post also limit infarct size but do not reduce myocardial dysfunction [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. The adenosine receptor agonist AMP579 or nitric oxide donors, on the other hand, alleviate both myocardial infarct size and dysfunction [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. The discrepancy between infarct limitation and cardiac function recovery may be explained by continued stunning, or the possibility that the salvaged tissue is not yet normal [<xref ref-type="bibr" rid="B11">11</xref>]. Myocardial stunning is prolonged myocardial dysfunction with the histological absence of necrosis after I/R injury. It is proposed that stunning occurs in reversibly injured cells or via nonlethal injury to the epicardial border zones surrounding infarcted myocardium [<xref ref-type="bibr" rid="B24">24</xref>]. Although cellular ATP levels or free radicals have been proposed to be important mediators for stunning [<xref ref-type="bibr" rid="B25">25</xref>], the exact mechanism responsible for stunning remains unclear. Another possible mechanism for myocardial stunning is an increase in the concentration of intracellular Ca<sup>2+</sup>. The increase in the Ca<sup>2+</sup> concentrations in myocardial cells is likely explains the depressed ability of I/R hearts to generate contractile force [<xref ref-type="bibr" rid="B26">26</xref>]. In our present study, targeting TPEN during the reperfusion period reduced myocardial infarction but did not attenuate post-ischemic systolic dysfunction, even though TPEN has a Ca<sup>2+</sup> buffer action. We do not know the exact reason for this, but the Ca<sup>2+</sup> buffer action of the TPEN concentration (10 &#x000b5;M) used during reperfusion might not be enough to attenuate myocardial systolic dysfunction.</p><p>It has been previously demonstrated that TPEN reduces basal cardiac nitric oxide (NO) content and prevents the accumulation of NO during myocardial I/R [<xref ref-type="bibr" rid="B9">9</xref>]. In addition it has been proposed that lowering sarcolemmal Ca<sup>2+</sup> content may be a mechanism underlying the recently reported cardioprotective and anti-arrhythmic features of TPEN [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. A chelator is a substance consisting of molecules that bind tightly to metal atoms, thus forcing the metal atoms to go wherever the chelator goes. Though TPEN has been used mainly as a heavy metal (e.g. Zn<sup>2+</sup>) chelator, it has a low affinity for Ca<sup>2+</sup> as well and its fast diffusion across membranes make TPEN a membrane permeable buffer for Ca<sup>2+</sup> within intracellular stores [<xref ref-type="bibr" rid="B8">8</xref>]. Recently, Shmist et al. [<xref ref-type="bibr" rid="B9">9</xref>] demonstrated that TPEN improves myocardial protection against ischemia by modulation of intracellular Ca<sup>2+</sup> homeostasis. Jung et al. [<xref ref-type="bibr" rid="B27">27</xref>] also demonstrated that myocardial protection by TPEN has been related to its modulation of Ca<sup>2+</sup> homeostasis through the activation of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger leading to increased extrusion of Ca<sup>2+</sup> from the cytoplasm in ventricular myocytes. However, the exact mechanism of the cardioprotective effect achieved by targeting the administration of TPEN during the reperfusion period has not yet been well established and should be determined in the future.</p><p>Interestingly, some drugs protect the myocardium when used during the ischemic phase but not in the reperfusion phase and vice versa [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. In this study, administrating TPEN during the reperfusion phase effectively reduced myocardial infarction. Taken together with other previous reports on the effect of PEN treatments targeting ischemia [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>], one can propose that TPEN has anti-ischemic and reperfusion injury protective effects.</p><p>It is also interesting that TPEN acts as a membrane permeable Zn<sup>2+</sup> chelator, i.e., TPEN reduces intracellular Zn<sup>2+</sup> concentrations. Zn<sup>2+</sup> is essential in maintaining the structure and function of cell membranes, and it plays an important role in the maintenance of the activity of various enzymes [<xref ref-type="bibr" rid="B28">28</xref>]. Recently, several lines of evidence documented that exogenous Zn<sup>2+</sup> may lead to cardioprotection against reperfusion injury [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. In our study, TPEN administration during the reperfusion phase significantly reduced myocardial infarction, even though TPEN reduces intracellular Zn<sup>2+</sup> concentrations. The reason for this is unclear, but we can propose that the Ca<sup>2+</sup> buffering effect of TPEN may be a more important mechanism for the limitation of infarction than the ability to lower the Zn<sup>2+</sup> concentration.</p><p>We conclude that P-Post with a 10 &#x000b5;M concentration of TPEN, which is proposed to have a cardioprotective effect during ischemia, limits myocardial infarction but does not attenuate myocardial dysfunction in isolated rat hearts. Further studies are needed to determine the exact mechanism for this discrepancy.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>This study was supported by Korea Medical Institute.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>ZQ</given-names></name><name><surname>Corvera</surname><given-names>JS</given-names></name><name><surname>Halkos</surname><given-names>ME</given-names></name><name><surname>Kerendi</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>NP</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2003</year><volume>285</volume><fpage>H579</fpage><lpage>H588</lpage><pub-id pub-id-type="pmid">12860564</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kin</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>ZQ</given-names></name><name><surname>Sun</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>NP</given-names></name><name><surname>Corvera</surname><given-names>JS</given-names></name><name><surname>Halkos</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion</article-title><source>Cardiovasc Res</source><year>2004</year><volume>62</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">15023554</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XC</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Ge</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention</article-title><source>J Invasive Cardiol</source><year>2007</year><volume>19</volume><fpage>424</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">17906344</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>ER</given-names></name><name><surname>Hsu</surname><given-names>AK</given-names></name><name><surname>Gross</surname><given-names>GJ</given-names></name></person-group><article-title>Opioid-induced cardioprotection occurs via glycogen synthase kinase &#x003b2; inhibition during reperfusion in intact rat hearts</article-title><source>Circ Res</source><year>2004</year><volume>94</volume><fpage>960</fpage><lpage>966</lpage><pub-id pub-id-type="pmid">14976126</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Mueller</surname><given-names>RA</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><article-title>Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3-beta</article-title><source>J Mol Cell Cardiol</source><year>2006</year><volume>40</volume><fpage>708</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">16516918</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baines</surname><given-names>CP</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>MV</given-names></name><name><surname>Downey</surname><given-names>JM</given-names></name></person-group><article-title>Myocardial protection by insulin is dependent on phosphatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart</article-title><source>Basic Res Cardiol</source><year>1999</year><volume>94</volume><fpage>188</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">10424237</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>JM</given-names></name><name><surname>Dusting</surname><given-names>GJ</given-names></name><name><surname>Woodman</surname><given-names>OL</given-names></name><name><surname>Ritchie</surname><given-names>RH</given-names></name></person-group><article-title>Cardioprotective action of CRF peptide urocotin against simulated ischemia in adult rat cardiomyocytes</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2003</year><volume>284</volume><fpage>H330</fpage><lpage>H336</lpage><pub-id pub-id-type="pmid">12388260</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shumaker</surname><given-names>DK</given-names></name><name><surname>Vann</surname><given-names>LR</given-names></name><name><surname>Goldberg</surname><given-names>MW</given-names></name><name><surname>Allen</surname><given-names>TD</given-names></name><name><surname>Wilson</surname><given-names>KL</given-names></name></person-group><article-title>TPEN, a Zn<sup>2+</sup>/Fe<sup>2+</sup> chelator with low affinity for Ca<sup>2+</sup>, inhibits lamin assembly, destabilizes nuclear architecture and may independently protect nuclei from apoptosis in vitro</article-title><source>Cell Calcium</source><year>1998</year><volume>23</volume><fpage>151</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">9601611</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shmist</surname><given-names>YA</given-names></name><name><surname>Kamburg</surname><given-names>R</given-names></name><name><surname>Ophir</surname><given-names>G</given-names></name><name><surname>Kozak</surname><given-names>A</given-names></name><name><surname>Shneyvays</surname><given-names>V</given-names></name><name><surname>Appelbaum</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>N,N,N',N'-tetrakis(2-pyridylmethyl)-ethylenediamine improves myocardial protection against ischemia by modulation of intracellular Ca<sup>2+</sup> homeostasis</article-title><source>J Pharmacol Exp Ther</source><year>2005</year><volume>313</volume><fpage>1046</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">15681657</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferdinandy</surname><given-names>P</given-names></name><name><surname>Appelbaum</surname><given-names>Y</given-names></name><name><surname>Csonka</surname><given-names>C</given-names></name><name><surname>Blasig</surname><given-names>IE</given-names></name><name><surname>Tosaki</surname><given-names>A</given-names></name></person-group><article-title>Role of nitric oxide and TPEN, a potent metal chelator in ischemic and reperfused rat isolated hearts</article-title><source>Clin Exp Pharmacol Physiol</source><year>1998</year><volume>25</volume><fpage>496</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">9673419</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lochner</surname><given-names>A</given-names></name><name><surname>Genade</surname><given-names>S</given-names></name><name><surname>Moolman</surname><given-names>JA</given-names></name></person-group><article-title>Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery</article-title><source>Basic Res Cardiol</source><year>2003</year><volume>98</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">12955407</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebel</surname><given-names>D</given-names></name><name><surname>Lipfert</surname><given-names>P</given-names></name><name><surname>Fr&#x000e4;ssdorf</surname><given-names>J</given-names></name><name><surname>Preckel</surname><given-names>B</given-names></name><name><surname>M&#x000fc;llenheim</surname><given-names>J</given-names></name><name><surname>Th&#x000e4;mer</surname><given-names>V</given-names></name><etal/></person-group><article-title>Lidocaine reduces ischaemic but not reperfusion injury in isolated rat heart</article-title><source>Br J Anaesth</source><year>2001</year><volume>86</volume><fpage>846</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">11573594</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Iliodoromitis</surname><given-names>EK</given-names></name><name><surname>O'Leary</surname><given-names>EL</given-names></name><name><surname>Ishimoto</surname><given-names>R</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species</article-title><source>Cardiovasc Res</source><year>1991</year><volume>25</volume><fpage>943</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">1813123</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heide</surname><given-names>RS</given-names></name><name><surname>Reimer</surname><given-names>KA</given-names></name></person-group><article-title>Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs</article-title><source>Cardiovasc Res</source><year>1996</year><volume>31</volume><fpage>711</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">8763400</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>Y</given-names></name><name><surname>Xi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Mueller</surname><given-names>RA</given-names></name><name><surname>Norfleet</surname><given-names>EA</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Postconditioning prevents reperfusion injury by activating &#x003b4;-opioid receptors</article-title><source>Anesthesiology</source><year>2008</year><volume>108</volume><fpage>243</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">18212569</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>DK</given-names></name><name><surname>Jang</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Chun</surname><given-names>KJ</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Polyphenol (-)-epigallocatechin gallate during ischemia limits infarct size via mitochondrial K<sub>ATP</sub> channel activation in isolated rat hearts</article-title><source>J Korean Med Sci</source><year>2010</year><volume>25</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">20191036</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appelbaum</surname><given-names>YJ</given-names></name><name><surname>Kuvin</surname><given-names>J</given-names></name><name><surname>Borman</surname><given-names>JB</given-names></name><name><surname>Uretzky</surname><given-names>G</given-names></name><name><surname>Chevion</surname><given-names>M</given-names></name></person-group><article-title>The protective role of neocuproine against cardiac damage in isolated perfused rat hearts</article-title><source>Free Radic Biol Med</source><year>1990</year><volume>8</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">2332193</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>R</given-names></name><name><surname>Foex</surname><given-names>P</given-names></name></person-group><article-title>Fentanyl reduces infarction but not stunning via delta opioid receptors and protein kinase C in rats</article-title><source>Br J Anaesth</source><year>2000</year><volume>84</volume><fpage>608</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">10844838</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>WR</given-names></name><name><surname>Clanachan</surname><given-names>AS</given-names></name></person-group><article-title>Angiotensin II reduces infarct size and has no effect on post-ischaemic contractile dysfunction in isolated rat hearts</article-title><source>Br J Pharmacol</source><year>2001</year><volume>134</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">11522595</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>DP</given-names></name><name><surname>Pugsley</surname><given-names>WB</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><article-title>Ischaemic preconditioning in a model of global ischaemia: infarct size limitation, but no reduction of stunning</article-title><source>J Mol Cell Cardiol</source><year>1995</year><volume>27</volume><fpage>1623</fpage><lpage>1632</lpage><pub-id pub-id-type="pmid">8523425</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couvreur</surname><given-names>N</given-names></name><name><surname>Lucats</surname><given-names>L</given-names></name><name><surname>Tissier</surname><given-names>R</given-names></name><name><surname>Bize</surname><given-names>A</given-names></name><name><surname>Berdeaux</surname><given-names>A</given-names></name><name><surname>Ghaleh</surname><given-names>B</given-names></name></person-group><article-title>Differential effects of postconditioning on myocardial stunning and infarction: a study in conscious dogs and anesthetized rabbits</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>291</volume><fpage>H1345</fpage><lpage>H1350</lpage><pub-id pub-id-type="pmid">16565317</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinmura</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>XL</given-names></name><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Hill</surname><given-names>M</given-names></name><name><surname>Bolli</surname><given-names>R</given-names></name></person-group><article-title>Nitric oxide donors attenuate myocardial stunning in conscious rabbits</article-title><source>Am J Physiol</source><year>1999</year><volume>277</volume><fpage>H2495</fpage><lpage>H2503</lpage><pub-id pub-id-type="pmid">10600874</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>Y</given-names></name><name><surname>Kristo</surname><given-names>G</given-names></name><name><surname>Keith</surname><given-names>BJ</given-names></name><name><surname>Jahania</surname><given-names>SA</given-names></name><name><surname>Mentzer</surname><given-names>RM</given-names><suffix>Jr</suffix></name><name><surname>Lasley</surname><given-names>RD</given-names></name></person-group><article-title>The p38 MAPK inhibitor SB203580 blocks adenosine A(1) receptor-induced attenuation of in vivo myocardial stunning</article-title><source>Cardiovasc Drugs Ther</source><year>2004</year><volume>18</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">15770430</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>LR</given-names></name><name><surname>Buja</surname><given-names>LM</given-names></name><name><surname>Samowitz</surname><given-names>W</given-names></name><name><surname>Rude</surname><given-names>RE</given-names></name><name><surname>Wathen</surname><given-names>M</given-names></name><name><surname>Tilton</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs. Comparison of 2- and 4-hours occlusions</article-title><source>Circ Res</source><year>1983</year><volume>53</volume><fpage>248</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">6883648</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloner</surname><given-names>RA</given-names></name><name><surname>DeBoer</surname><given-names>LW</given-names></name><name><surname>Darsee</surname><given-names>JR</given-names></name><name><surname>Ingwall</surname><given-names>JS</given-names></name><name><surname>Hale</surname><given-names>S</given-names></name><name><surname>Tumas</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prolonged abnormalities of myocardium salvaged by reperfusion</article-title><source>Am J Physiol</source><year>1981</year><volume>241</volume><fpage>H591</fpage><lpage>H599</lpage><pub-id pub-id-type="pmid">7315984</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>JP</given-names></name></person-group><article-title>Contractile dysfunction and abnormal Ca<sup>2+</sup> modulation during postischemic reperfusion in rat heart</article-title><source>Am J Physiol</source><year>1995</year><volume>268</volume><fpage>H100</fpage><lpage>H111</lpage><pub-id pub-id-type="pmid">7840255</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Zima</surname><given-names>AV</given-names></name><name><surname>Szentesi</surname><given-names>P</given-names></name><name><surname>Jona</surname><given-names>I</given-names></name><name><surname>Blatter</surname><given-names>LA</given-names></name><name><surname>Niggli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Ca<sup>2+</sup> release from the sarcoplasmic reticulum activated by the low affinity Ca<sup>2+</sup> chelator TPEN in ventricular myocytes</article-title><source>Cell Calcium</source><year>2007</year><volume>41</volume><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">16920191</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Dell</surname><given-names>BL</given-names></name></person-group><article-title>Zinc plays both structural and catalytic roles in metalloproteins</article-title><source>Nutr Rev</source><year>1992</year><volume>50</volume><fpage>48</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">1570083</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanoit</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Xi</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>McIntosh</surname><given-names>RA</given-names></name><name><surname>Mueller</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2008</year><volume>295</volume><fpage>H1227</fpage><lpage>H1233</lpage><pub-id pub-id-type="pmid">18660440</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Chanoit</surname><given-names>G</given-names></name><name><surname>McIntosh</surname><given-names>R</given-names></name><name><surname>Zvara</surname><given-names>DA</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><article-title>Molecular mechanism under lying Akt act ivat ion in zinc-induced cardioprotection</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2009</year><volume>297</volume><fpage>H569</fpage><lpage>H575</lpage><pub-id pub-id-type="pmid">19525380</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Experimental protocol of isolated heart perfusion. Rats were subject to 30 min of regional ischemia followed by 2 h of reperfusion. TPEN (N,N,N'N'-Tetrakis-[2-pyridylmethyl]-ethylenediamine) was perfused for a period of 35 min, from 5 min before reperfusion to 30 min after reperfusion (dashed box).</p></caption><graphic xlink:href="kjae-58-290-g001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Area of necrosis (AN) as percentage of area at risk (AR) as evaluated by triphenyltetrazolium chloride (TTC) staining following 30 min of regional ischemia and 2 h of reperfusion in an isolated rat heart model. AN/AR significantly decreased in TPEN-treated hearts compared to untreated control hearts. Open circles indicate the infarct sizes from individual hearts. Filled circles in each group indicate the group mean infarct size; mean &#x000b1; SEM. TPEN: N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine. <sup>*</sup>P &#x0003c; 0.001 vs. control.</p></caption><graphic xlink:href="kjae-58-290-g002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><p>Percentage changes in left ventricular developed pressure (LVDP), rate-pressure product (RPP), velocity of contraction (+dP/dt<sub>max</sub>), and velocity of relaxation (-dP/dt<sub>min</sub>) after 2 h of reperfusion compared to baseline levels in isolated rat hearts. There were no significant differences in cardiodynamic variables between the two groups. TPEN: N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine. Values are means &#x000b1; SEM.</p></caption><graphic xlink:href="kjae-58-290-g003"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline Coronary Flow and Cardiodynamic Data after Stabilization</p></caption><graphic xlink:href="kjae-58-290-i001"/><table-wrap-foot><fn><p>Values are means &#x000b1; SEM. TPEN: N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine, LVDP: left ventricular developed pressure, RPP: rate-pressure product, +dP/dt<sub>max</sub>: velocity of contraction, -dP/dt<sub>min</sub>: velocity of relaxation. There are no significant differences between groups (<italic>t</italic>-test).</p></fn></table-wrap-foot></table-wrap></floats-group></article>